Icon

Alimera Sciences Inc Stock Analysis and Price Target COMMON STOCK | Drug Manufacturers-Specialty & Generic | NSD

N/A

Average User
Rating
stockTargetAdvisor

Hold

Average Analyst
Rating
stockTargetAdvisor

Hold

Top Analyst
Rating
stockTargetAdvisor

Bearish

Stock Target Advisor
Analysis

USD 1.64

0.00 (0.00)%

USD 0.01B

0.06M

USD 4.50(+174.39%)

N/A

Icon

ALIM

Alimera Sciences Inc (USD)
COMMON STOCK | NSD
USD 1.64
0.00 0

N/A

Average User
Rating
stockTargetAdvisor

Hold

Average Analyst
Rating
stockTargetAdvisor

Hold

Top Analyst
Rating
stockTargetAdvisor

Bearish

Stock Target Advisor
Analysis

USD 0.01B

N/A

USD 1.64

Alimera Sciences Inc Stock Forecast

Show ratings and price targets of :
USD 4.50
(+174.39%)

Based on the Alimera Sciences Inc stock forecasts from 1 analysts, the average analyst target price for Alimera Sciences Inc is USD 4.50 over the next 12 months. Alimera Sciences Inc’s average analyst rating is Hold . Stock Target Advisor’s own stock analysis of Alimera Sciences Inc is Bearish, which is based on 2 positive signals and 6 negative signals. At the last closing, Alimera Sciences Inc’s stock price was USD 1.64. Alimera Sciences Inc’s stock price has changed by -4.65% over the past week, -31.38% over the past month and -70.18% over the last year.

No recent analyst target price found for Alimera Sciences Inc
No recent average analyst rating found for Alimera Sciences Inc

Company Overview

Alimera Sciences, Inc., a pharmaceutical company, engages in the development and commercialization of ophthalmic pharmaceuticals in the United States and internationally. It offers ILUVIEN, an intravitreal implant for the treatment of diabetic macular edema (DME), which is a dise...Read More

https://alimerasciences.com

6310 Town Square, Alpharetta, GA, United States, 30005

145

December

USD

USA

Adjusted Closing Price

Loading...

Technical Indicators

Unadjusted Closing Price

Loading...

Assets

Top Holdings

Top Sectors

Top Regions

Share Volume

Loading...

Relative Performance

Symbol Capital Gain Dividend Return Total Return
Loading...

Stocks Similar To Alimera Sciences Inc (Sector: Drug Manufacturers-Specialty & Generic )

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
PPD
PPD Inc 0.00 (0.00%) USD16.61B 47.04 21.58

ETFs Containing ALIM

Symbol Name Weight Mer Price(Change) Market Cap
no data

Frequently Asked Questions About ALIM Stock

Based on ratings from 1 analysts Alimera Sciences Inc's stock is Hold . Stock Target Advisor's fundamental analysis is Bearish. The stock has buy, sell and 1 hold ratings.

Unfortunately we do not have enough data on ALIM's stock to indicate if its a good dividend stock.

Based on targets from 1 analysts, the average taret price for ALIM is USD 4.50 over the next 12 months. The maximum analyst target price is USD 4.5 while the minimum anlayst target price is USD 4.5.

ALIM stock's Price/Earning ratio is 12.81. Our analysis grades ALIM stock's Price / Earning ratio at F. This means that ALIM stock's Price/Earning ratio is above 46% of the stocks in the Drug Manufacturers-Specialty & Generic sector in the NSD exchange. Based on this ALIM may be fairly valued for its sector

The last closing price of ALIM's stock was USD 1.64.

The most recent market capitalization for ALIM is USD 0.01B.

Based on targets from 1 analysts, the average taret price for ALIM is projected at USD 4.50 over the next 12 months. This means that ALIM's stock price may go up by +174.39% over the next 12 months.
Heading 1 Heading 2 Heading 3 Heading 4 Heading 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5

Stock Target Advisor's Analysis

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

Icon
What to like

Icon
What not to like

Loading...